FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washing

ton, D.C. 20549	
Jton, D.C. 20049	OMB APPROVA
	OMB/II NOV/

- 1		
	OMB Number:	3235-0287
	Estimated average burde	en
	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Russo Rene					2. Issuer Name and Ticker or Trading Symbol Xilio Therapeutics, Inc. [XLO]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) 828 WINTER STREET					3. Date of Earliest Transaction (Month/Day/Year) 08/16/2023								X	Officer (below)	Other (sp below)	pecify		
SUITE 300					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc Line)					
(Street) WALTH	AM M	ΊΑ	02451											X Form filed by One Reporting Person Form filed by More than One Reporting Person				ng
(City)	(S	tate)	(Zip)	ı-Deriv	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Vative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.					Execution Date,		Code (Ins	etr.		r. 3, 4 and 5	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		. Nature of ndirect eneficial ownership nstr. 4)			
			Table II - [Derivat e.g., p	tive outs,	Sec call	urities . s, warr	Acq ants	uired, Dis s, options	posed o	f, or	Bene secu	ficially (Owned			·	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	Co	e, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	ode	v	(A) (D	(D)	Date Exercisable	Expiration Date	Title		Amount or Number of Shares		(Instr. 4)			
Stock Option (right to buy)	\$2.785	08/16/2023		I	A		700,000		(1)	08/15/203		nmon ock	700,000	\$0	700,00	00	D	

Explanation of Responses:

1. The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date.

/s/ Chris Frankenfield, 08/18/2023 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.